Wockhardt Limited (NSE: WOCKPHARMA)

Market Cap	158.71B
Revenue (ttm)	29.25B
Net Income (ttm)	-3.43B
Shares Out	153.41M
EPS (ttm)	-23.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	315,183
Open	1,089.90
Previous Close	1,089.00
Day's Range	1,034.55 - 1,089.90
52-Week Range	213.25 - 1,097.70
Beta	1.67
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Wockhardt

Wockhardt Limited, a pharmaceutical and biotech company, manufactures and markets pharmaceuticals, medicinal, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Mexico, Russia, and internationally. It develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules; and active pharmaceutical ingredients. The company’s biopharmaceutical products include Glaritus, a long-acting biosimilar glargine; Wosulin, a recom...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1967
• Employees: 2,386
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: WOCKPHARMA

Financial Performance

In 2023, Wockhardt's revenue was 28.30 billion, an increase of 6.51% compared to the previous year's 26.57 billion. Losses were -4.63 billion, -17.17% less than in 2022.